Medicines labeled for the same conditions
Alternatives to golimumab
8 other medicines are given the same way (subcutaneous) and in the same FDA class as golimumab or labeled mainly for the same use (rheumatoid arthritis); 3 are in its class, tumor necrosis factor blockers: adalimumab, etanercept and certolizumab; the others include 2 interleukin-6 receptor antagonists, 1 folate analog metabolic inhibitor and 1 selective t cell costimulation modulator (FDA labels read October 8, 2026). In the same class, the lowest pharmacy cost is $1,587.82 per mL (Adalimumab-adaz(cf) pen 40 mg/0.4 mL) (what pharmacies paid in the NADAC survey; strengths differ).
Which medicines are labeled for the same conditions as golimumab?
Rheumatoid arthritis lists all 46 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Golimumabtumor necrosis factor blocker | this medicine | none listed | $12,890.32 per mL 50 mg/0.5 mL pen injec | Yes | No current entry |
| Adalimumabtumor necrosis factor blocker · same class | Rheumatoid arthritis, Crohn's disease and ulcerative colitis | none listed | $1,587.82 per mL 40 mg/0.4 mL | Yes | No current entry |
| Etanercepttumor necrosis factor blocker · same class | Rheumatoid arthritis | none listed | $2,084.14 per mL 25 mg/0.5 mL syringe | Yes | No current entry |
| Certolizumabtumor necrosis factor blocker · same class | Rheumatoid arthritis, Crohn's disease and ulcerative colitis | none listed | $6,094.02 per syringe 2x200 mg/mL syringe kit | Yes | No current entry |
| Methotrexatefolate analog metabolic inhibitor | Rheumatoid arthritis | none listed | $289.37 per mL 25 mg/0.5 mL autoinj | Yes | In shortage |
| Tocilizumabinterleukin-6 receptor antagonist | Rheumatoid arthritis | none listed | $821.00 per mL 162 mg/0.9 mL autoinjct | Yes | No current entry |
| Sarilumabinterleukin-6 receptor antagonist | Rheumatoid arthritis | none listed | $2,075.30 per mL 200 mg/1.14 mL pen injection | Yes | No current entry |
| Abataceptselective t cell costimulation modulator | Rheumatoid arthritis | none listed | $1,469.23 per mL 125 mg/mL syringe | No | No current entry |
| Adalimumab-aacf | Rheumatoid arthritis, Crohn's disease and ulcerative colitis | none listed | n/a | Yes | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Golimumab: the full record
- label, generics, price, shortages, recalls
- Adalimumab vs golimumab
- two records side by side
- Etanercept vs golimumab
- two records side by side
- Certolizumab vs golimumab
- two records side by side